UK: Pharmaron Beijing acquires Aesica Pharmaceuticals from Recipharm

Pharmaron Beijing, an R&D service provider for the life sciences industry, has acquired Aesica Pharmaceuticals (The Cramlington Site) from pharmaceutical industry CDMO, Recipharm. The Cramlington Site in Newcastle, UK, has more than 100 cubic meter reactor commercial capacity and has been inspected and approved by the MHRA, FDA and other regulatory authorities. The acquisition expands…

You must be a HMI Subscriber to view this content.

Subscribe Now »